LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
31 hedge funds and large institutions have $304K invested in LakeShore Biopharma Warrants in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
90% less capital invested
Capital invested by funds: $3.07M → $304K (-$2.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$17K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$382 |
| 3 |
CS
Clear Street
New York
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Segantii Capital Management
Hong Kong
|
-$320K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$15.6K |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$2.47K |
| 4 |
ETH
Exos TFP Holdings
New York
|
-$85 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HIM
26
HGC Investment Management
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
SIA
27
SkyView Investment Advisors
Shrewsbury,
New Jersey
| $1K | – | – | – |
|
|
LCM
28
Landscape Capital Management
Englewood,
New Jersey
| $470 | – | – | – |
|
|
AA
29
Ancora Advisors
Cleveland,
Ohio
| $237 | – | – | – |
|
|
30
UBS Group
Zurich,
Switzerland
| $211 | +$382 | +4,493 | New |
|
|
AC
31
Athos Capital
Hong Kong
| $207 | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $6 | – | – | – |
|
|
SCM
33
Segantii Capital Management
Hong Kong
| – | -$320K | -200,000 | Closed |
|
|
PC
34
Periscope Capital
Toronto,
Ontario, Canada
| – | -$15.6K | -100,000 | Closed |
|
LSBPW Hedge Fund Activity: Q2 2023 in Review
31 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q2 2023, worth a combined $304K — down 90% from $3.07M a quarter earlier.
Fund positioning in LSBPW was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $17K. The largest seller was Segantii Capital Management, exiting entirely with an estimated $320K sold.
- 31 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $304K of LakeShore Biopharma Warrants stock for Q2 2023, down 90% quarter-over-quarter.
- 2 funds opened new LakeShore Biopharma Warrants positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest LakeShore Biopharma Warrants buyer in Q2 2023 was Cowen and Company, an estimated $17K added.
- The largest LakeShore Biopharma Warrants seller in Q2 2023 was Segantii Capital Management, an estimated $320K sold.
Based on aggregated 13F filings for Q2 2023.